



## APPENDIX

### PENDING CLAIMS

1                   3.     A system for averting undesirable drug interaction between a drug  
2     and concomitant drug(s), both of which are metabolized by the same molecular species of  
3     drug-metabolizing enzyme in humans, or between a drug and concomitant drug(s) that is  
4     metabolized by the molecular species of drug-metabolizing enzymes that is inhibited by  
5     the said drug, which comprises timed-release control of the said drug or control of the site  
6     of release of the said drug to the digestive tract.

1                   4.     A system for averting undesirable drug interaction between a drug  
2     and concomitant drug(s), both of which metabolized by the drug metabolizing enzyme  
3     CYP3A4, or between a drug that inhibits CYP3A4 and concomitant drug(s) that is  
4     metabolized by CYP3A4, which comprises timed-release control of the said drug or  
5     controlling release specifically in the lower digestive tract of the said drug.

1                   7.     A drug preparation for averting undesirable drug interaction on the  
2     *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the  
3     said drug in humans, which comprises timed-release control of the concomitant drug or  
4     control of the site of release of the concomitant drug to the digestive tract.

1                   8.     A drug preparation for averting undesirable effects on the blood  
2     concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the  
3     said drug by CYP3A4 in humans, which comprises timed release control of the said drug  
4     or controlling release specifically in the lower digestive tract of the concomitant drug.

1                   9.     The drug preparation according to Claim 8, whereby the said drug  
2     and the concomitant drug are a combination selected from anfenfentanyl, fentanyl,  
3     sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin,  
4     clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone,  
5     midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,

6 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,  
7 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,  
8 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
9 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
10 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
11 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
12 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
13 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
14 ondanteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and  
15 conivaptan.

1                   12.     A method for averting undesirable drug-interaction on the *in vivo*  
2 kinetics of a drug by concomitant drug that inhibits the *in vivo* metabolism of the said  
3 drug by drug-metabolizing enzymes in humans, comprising administering to patients a  
4 drug preparation with which timed-release of the concomitant drug or release site of the  
5 concomitant drug to the digestive tract is controllable.

1                   13.     A method for averting undesirable effects on the blood  
2 concentration of a drug by concomitant drug that inhibits the *in vivo* metabolism of the  
3 said drug by CYP3A4, comprising administering to patients a drug preparation with  
4 which timed-release of the concomitant drug or release of the concomitant drug  
5 specifically to the lower digestive tract is controllable.

1                   14.     The method according to Claim 13, whereby the said drug and the  
2 concomitant drug are a combination selected from anfentanyl, fentanyl, sulfentanyl,  
3 cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin, clarithromycin,  
4 troleandomycin, azithromycin, itraconazole, ketoconazole, dapson, midazolam,  
5 triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine, nitrendipine,  
6 amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine, bepridil,  
7 diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine, tacrolimus,  
8 rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine, imipramine,  
9 amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol, pimozide,

10 carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin, fluvastatin,  
11 atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine, vincristine,  
12 indinavir, ritonavir, saquinavir, testosterone, prednisolone, methylprednisolone,  
13 dexamethasone, proguanil, warfarin, finasteride, flutamide, ondasteron, zatsetrone,  
14 cisapride, cortisol, zonisamide, desmethyldiazepam, and conivaptan.

1 16. A drug preparation for averting undesirable effects on the blood  
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the  
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug  
4 or controlling release specifically in the lower digestive tract of the concomitant drug,  
5 whereby:

6 the said drug and the concomitant drug are a combination selected from  
7 anfantanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,  
8 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,  
9 dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,  
10 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,  
11 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,  
12 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
13 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
14 pimozone, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
15 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
16 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
17 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
18 ondasteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and  
19 conivaptan.

1 17. A drug preparation for averting undesirable drug interaction on the  
2 *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the  
3 said drug in humans, which comprises timed-release control of the concomitant drug or  
4 control of the site of release of the concomitant drug to the digestive tract whereby:

5                   the said drug and the concomitant drug are a combination selected from  
6   anfentanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,  
7   erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,  
8   dapson, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,  
9   nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,  
10   bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,  
11   tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,  
12   imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,  
13   pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,  
14   fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,  
15   vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,  
16   methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,  
17   ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and  
18   conivaptan.

1                   18. (New)    The system for averting undesirable drug interaction of  
2   claim 3, wherein said drug and the concomitant drug are both metabolized by the same  
3   molecular species of drug-metabolizing enzyme in humans.

1                   19. (New)    The system for averting undesirable drug interaction of  
2   claim 3, wherein the concomitant drug is metabolized by the molecular species of the  
3   drug-metabolizing enzymes that is inhibited by the said drug.

1                   20. (New)    The system for averting undesirable drug interaction of  
2   claim 18, wherein said drug and the concomitant drug are both metabolized by CYP3A4.

1                   21. (New)    The system for averting undesirable drug interaction of  
2   claim 19, the concomitant drug is metabolized by CYP3A4 and said drug inhibits  
3   CYP3A4.